Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

CARE-MS | Investigators; Raymond Hupperts

doi:10.1016/S0140-6736(12)61768-1

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

CARE-MS | Investigators
, Raymond Hupperts

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background the anti-cd52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.

Original language	English
Pages (from-to)	1829-1839
Number of pages	11
Journal	Lancet
Volume	380
Issue number	9856
DOIs	https://doi.org/10.1016/S0140-6736(12)61768-1
Publication status	Published - 24 Nov 2012

Access to Document

10.1016/S0140-6736(12)61768-1

Cite this

@article{b4ba4d3873ce414ea50a3833ddc20039,

title = "Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial",

abstract = "Background the anti-cd52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.",

author = "Coles, \{Alasdair J.\} and Twyman, \{Cary L.\} and Arnold, \{Douglas L.\} and Cohen, \{Jeffrey A.\} and Christian Confavreux and Fox, \{Edward J.\} and Hans-Peter Hartung and Eva Havrdova and Selmaj, \{Krzysztof W.\} and Weiner, \{Howard L.\} and Tamara Miller and Elizabeth Fisher and Rupert Sandbrink and Lake, \{Stephen L.\} and Margolin, \{David H.\} and Pedro Oyuela and Panzara, \{Michael A.\} and \{CARE-MS | Investigators\} and Raymond Hupperts and Compston, \{D. Alastair S.\}",

year = "2012",

month = nov,

day = "24",

doi = "10.1016/S0140-6736(12)61768-1",

language = "English",

volume = "380",

pages = "1829--1839",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "9856",

}

TY - JOUR

T1 - Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

AU - Coles, Alasdair J.

AU - Twyman, Cary L.

AU - Arnold, Douglas L.

AU - Cohen, Jeffrey A.

AU - Confavreux, Christian

AU - Fox, Edward J.

AU - Hartung, Hans-Peter

AU - Havrdova, Eva

AU - Selmaj, Krzysztof W.

AU - Weiner, Howard L.

AU - Miller, Tamara

AU - Fisher, Elizabeth

AU - Sandbrink, Rupert

AU - Lake, Stephen L.

AU - Margolin, David H.

AU - Oyuela, Pedro

AU - Panzara, Michael A.

AU - CARE-MS | Investigators

AU - Hupperts, Raymond

AU - Compston, D. Alastair S.

PY - 2012/11/24

Y1 - 2012/11/24

N2 - Background the anti-cd52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.

AB - Background the anti-cd52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.

U2 - 10.1016/S0140-6736(12)61768-1

DO - 10.1016/S0140-6736(12)61768-1

M3 - Article

SN - 0140-6736

VL - 380

SP - 1829

EP - 1839

JO - Lancet

JF - Lancet

IS - 9856

ER -

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Abstract

Access to Document

Fingerprint

Cite this